Shanghai Labway Clinical Laboratory Co., Ltd. () Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Shanghai Labway Clinical Laboratory Co., Ltd.

Why is Shanghai Labway Clinical Laboratory Co., Ltd. ?

Poor long term growth as Net Sales has grown by an annual rate of -6.03% and Operating profit at -23.44% over the last 5 years

Positive results in Mar 26

ROCE(HY) Highest at 0.88%
RAW MATERIAL COST(Y) Fallen by -63.34% (YoY)
DEBT-EQUITY RATIO (HY) Lowest at -43.38 %

With ROE of 3.07%, it has a very expensive valuation with a 1.90 Price to Book Value

Over the past year, while the stock has generated a return of -8.99%, its profits have risen by 149.3% ; the PEG ratio of the company is 0.4

Below par performance in long term as well as near term

Along with generating -8.99% returns in the last 1 year, the stock has also underperformed China Shanghai Composite in the last 3 years, 1 year and 3 months

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to Shanghai Labway Clinical Laboratory Co., Ltd. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Shanghai Labway Clinical Laboratory Co., Ltd. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Shanghai Labway Clinical Laboratory Co., Ltd.

12.62%

-0.04

44.05%

China Shanghai Composite

6.61%

1.20

14.07%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-6.03%

EBIT Growth (5y)

-23.44%

EBIT to Interest (avg)

57.10

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.33

Sales to Capital Employed (avg)

0.84

Tax Ratio

49.88%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

16.09%

ROE (avg)

12.06%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

2.03

EV to EBIT

40.51

EV to EBITDA

23.57

EV to Capital Employed

2.83

EV to Sales

1.83

PEG Ratio

0.44

Dividend Yield

1.99%

ROCE (Latest)

6.99%

ROE (Latest)

3.07%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bullish

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bullish

Bullish

Dow Theory

Mildly Bullish

OBV

Mildly Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

24What is working for the Company

ROCE(HY)

Highest at 0.88%

RAW MATERIAL COST(Y)

Fallen by -63.34% (YoY

DEBT-EQUITY RATIO (HY)

Lowest at -43.38 %

DEBTORS TURNOVER RATIO(HY)

Highest at 1.89 times

OPERATING PROFIT MARGIN(Q)

Highest at 14.18 %

PRE-TAX PROFIT(Q)

Highest at CNY 46.07 MM

NET PROFIT(Q)

Highest at CNY 36.91 MM

EPS(Q)

Highest at CNY 0.09

-11What is not working for the Company

INVENTORY TURNOVER RATIO(HY)

Lowest at 3 times

NET SALES(Q)

Lowest at CNY 287.16 MM

Here's what is working for Shanghai Labway Clinical Laboratory Co., Ltd.

Pre-Tax Profit

At CNY 46.07 MM has Grown at 751.65%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is very positive

Pre-Tax Profit (CNY MM)

Net Profit

At CNY 36.91 MM has Grown at 553.89%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is very positive

Net Profit (CNY MM)

Operating Profit Margin

Highest at 14.18 %

in the last five periods

MOJO Watch

Company's profit margin has improved

Operating Profit to Sales

Pre-Tax Profit

Highest at CNY 46.07 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (CNY MM)

Net Profit

Highest at CNY 36.91 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is positive

Net Profit (CNY MM)

EPS

Highest at CNY 0.09

in the last five periods

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (CNY)

Debt-Equity Ratio

Lowest at -43.38 %

in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Debtors Turnover Ratio

Highest at 1.89 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Raw Material Cost

Fallen by -63.34% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Shanghai Labway Clinical Laboratory Co., Ltd.

Net Sales

At CNY 287.16 MM has Fallen at -17.83%

Year on Year (YoY)

MOJO Watch

Near term sales trend is very negative

Net Sales (CNY MM)

Net Sales

Lowest at CNY 287.16 MM

in the last five periods

MOJO Watch

Near term sales trend is negative

Net Sales (CNY MM)

Inventory Turnover Ratio

Lowest at 3 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling inventory has slowed

Inventory Turnover Ratio